Consumers have access to more health information and probiotic products than ever, yet that abundance of choice may be creating confusion rather than confidence.
New consumer research from IFF Health Sciences suggests a disconnect between consumers’ confidence in their health decisions and their ability to act on available information. While 82% of supplement consumers say they feel at least moderately confident in their long-term health decisions, nearly 6 in 10 admit they’ve delayed taking action on a health goal in the past year because they couldn’t make sense of the available information.¹
For probiotic brands and formulators, this presents an opportunity to rethink how products are developed, differentiated, and communicated. Rather than relying primarily on CFU (colony forming unit) counts or broad wellness claims, the industry can build consumer trust through strain-specific clinical evidence, meaningful health outcomes, and greater transparency.
While viable cell counts, as CFUs, are important, a higher number does not automatically translate into greater efficacy. Further, health benefits are strain-specific, making it critical to understand the probiotic identity, dose, and clinical evidence for an intended application. This is particularly important as probiotics are gaining traction outside of the traditional digestive health space into all aspects of the “Gut-X” axis and categories such as cognitive wellbeing, immune support, and metabolic health.
IFF Health Sciences has extended its HOWARU® probiotic portfolio to serve multiple health categories and applications, including its Signature Strains, developed around targeted, evidence-based benefits, and Essential Strains for broader formulation requirements. IFF emphasizes genomic strain identity, stability, safety, and clinical efficacy within its HOWARU® platform. Its Signature Strains are evaluated through the company’s VERIFY protocol, designed to establish standards for ingredient quality and scientific substantiation.
Internal Internal For brands, this affords the opportunity to start product development from a clearly defined consumer health need and select strains supported by relevant clinical research. Rigorous clinical studies must consider factors including strain identification, appropriate dosing, participant characteristics, relevant health outcomes, and robust study design.
For formulators and ingredient buyers, understanding the strength and relevance of the underlying research is essential to evaluating potential product benefits. Clinical evidence also creates a foundation for credible consumer communication. The challenge is not simply producing more research, but translating substantiated findings into benefits and product experiences that accurately reflect what the science demonstrates.
Science in action: A gut-first approach to metabolic health
One example of this approach is IFF’s recently introduced HOWARU GutABAlite™, featuring Levilactobacillus brevis LBR-6108™, a probiotic strain that produces gamma-aminobutyric acid (GABA) in the gut.
Although GABA is widely recognized for its role as an inhibitory neurotransmitter, it also participates in physiological processes relevant to metabolic function. This creates opportunities to investigate how microbial activity in the gut may influence glucose regulation and insulin signaling.
In a six-week randomized, double-blind, placebo-controlled human study reported by IFF, supplementation with GutABAlite™ was associated with gut GABA production, increased beneficial short-chain fatty acids, and favorable changes in glucose and insulin measures compared with placebo.
Participants receiving the probiotic showed statistically significant lower daily glucose exposure, alongside trends toward lower fasting insulin and lower HOMA-IR, a measure used to estimate insulin resistance. IFF reported that the effects diminished following discontinuation of supplementation.
These findings offer an emerging example of how strain-specific research can connect microbial activity with measurable physiological outcomes. While the insulin findings are preliminary and further research is needed to establish their clinical significance and durability, the study illustrates how probiotic innovation is extending into new areas of health and wellness.
From scientific discovery to commercial differentiation
Internal Internal For CPG brands and product developers, selecting a clinically studied strain is only one component of creating a successful probiotic product. Manufacturing consistency, strain stability, appropriate dosing, formulation compatibility, and regulatory considerations all influence whether scientific findings can be translated into commercially viable products.
This makes the relationship between brands and ingredient suppliers increasingly important, as supplier selection can influence product quality, substantiation and the ability to communicate benefits credibly.
IFF positions its probiotic capabilities around a comprehensive approach from strain selection and manufacturing to product development, while its broad portfolio allows customers to explore different health applications and finished-product formats.
Ultimately, the value of clinical investment extends beyond supporting individual ingredient claims. It can help brands make more informed formulation decisions, establish meaningful differentiation, and communicate realistic expectations to consumers.
IFF’s forthcoming consumer research reinforces the importance of this approach. When asked what would help consumers make more confident health decisions, 33% prioritized better proof that products work, compared with just 14% who wanted more health information.
The implication is clear: Competitive advantage increasingly depends not on providing more information or bigger numbers, but on delivering credible evidence that connects specific ingredients with meaningful health benefits.
References
- IFF Health Confidence Study, conducted through Suzy among 1,000 U.S. adults ages 75–18 who reported using a dietary supplement within the previous six months. Findings describe surveyed supplement users.







